169 related articles for article (PubMed ID: 24924525)
1. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila J; Carrato A; Tabernero J; Grande E
Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
[TBL] [Abstract][Full Text] [Related]
2. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract][Full Text] [Related]
3. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor.
Reck M
Expert Rev Anticancer Ther; 2015 May; 15(5):579-94. PubMed ID: 25831142
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
6. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R
Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421
[TBL] [Abstract][Full Text] [Related]
8. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
9. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
Antoniu SA; Kolb MR
IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191
[TBL] [Abstract][Full Text] [Related]
10. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
Roth GJ; Heckel A; Colbatzky F; Handschuh S; Kley J; Lehmann-Lintz T; Lotz R; Tontsch-Grunt U; Walter R; Hilberg F
J Med Chem; 2009 Jul; 52(14):4466-80. PubMed ID: 19522465
[TBL] [Abstract][Full Text] [Related]
12. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
[TBL] [Abstract][Full Text] [Related]
13. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
Altunel E; Roghani RS; Chen KY; Kim SY; McCall S; Ware KE; Shen X; Somarelli JA; Hsu DS
BMC Cancer; 2020 Jun; 20(1):592. PubMed ID: 32580713
[TBL] [Abstract][Full Text] [Related]
14. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
Kutluk Cenik B; Ostapoff KT; Gerber DE; Brekken RA
Mol Cancer Ther; 2013 Jun; 12(6):992-1001. PubMed ID: 23729403
[TBL] [Abstract][Full Text] [Related]
15. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
[TBL] [Abstract][Full Text] [Related]
16. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
17. SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.
Jiang XF; Dai Y; Peng X; Shen YY; Su Y; Wei MM; Liu WR; Ding ZB; Zhang A; Shi YH; Ai J
Acta Pharmacol Sin; 2018 Feb; 39(2):243-250. PubMed ID: 28905937
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma.
Patwardhan PP; Musi E; Schwartz GK
Mol Cancer Ther; 2018 Nov; 17(11):2329-2340. PubMed ID: 30166401
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats.
de Raaf MA; Herrmann FE; Schalij I; de Man FS; Vonk-Noordegraaf A; Guignabert C; Wollin L; Bogaard HJ
Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H604-12. PubMed ID: 27342880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]